The world of protein design has taken a giant leap forward with the creation of enzymes almost as effective as nature's own. But here's where it gets controversial: the new model, RoseTTAFold Diffusion, has not only designed enzymes from scratch but has also achieved results that rival the efficiency of natural enzymes. This groundbreaking development, led by 2024 Nobel prize-winner David Baker, has the potential to revolutionize biotechnology and open up new avenues for synthetic biology.
Enzymes, the unsung heroes of life, are responsible for catalyzing complex chemical reactions that provide cells with energy, nutrients, and materials. They are the workhorses of life, and their design has always been a challenging task due to their complex and dynamic nature. Rohith Krishna, a postdoctoral fellow at the University of Washington, highlights two main hurdles in enzyme design: the struggle with non-protein interactions and the precise positioning of protein side chains in the catalytic or active site of the enzyme.
The new model, RF Diffusion 2, has overcome these challenges by expanding the model to include side chain atoms and relaxing other parameters. This has allowed the model to decide for itself the best sequence order, resulting in a diverse range of designs. The team's efforts have paid off, as they were able to create zinc-based enzymes that break ester bonds with enzymatic activities close to those found in nature.
However, the success rate for highly efficient enzymes is still in the ~1% range, which means many designs need to be synthesized and screened. This is a costly and time-consuming process, and other properties need to be assessed, such as how suitable the enzymes might be for a given industrial environment like a bioreactor. Despite these challenges, the speed of developments, such as the release of RF Diffusion 3, is encouraging. RF Diffusion 3 is now freely available and handles more non-protein molecules and catalytic sites, and is 10 times faster and more precise at placing those atoms.
This development is exciting for biochemists like Steffen Lindner-Mehlich, who sees the potential for novel enzymes to 'design tailored synthetic pathways' for a variety of new applications. However, it also raises questions about the future of protein design and the potential impact on biotechnology and synthetic biology. Will this technology be accessible to all, or will it be limited to those with the resources to synthesize and screen a large number of designs? And what are the ethical implications of creating enzymes that rival the efficiency of nature's own?
